Ciprofloxacin is one of the quinolones that have inibitory activity against Mycobacterium tuberculosis and Mycobacterium avium complex (in vitro at concentrations of 1.3 g/ml for M. tuberculosis and 10 to 100 g/ml for M. avium complex bacteria) and it has been used as part of three-drug and four-drug regimens for MAC infections in HIV-infected patients. The aim of our search is to enhance the potency of some new derivatives, in particular, toward strains of Mycobacterium avium.
The piperazine ring of ciprofloxacin is connected throught an etanone bridge to the 4,5-dihydro-1H-pirazole-3,5-disubstituted moiety
